Alonso BSA, Arroyo ZOJ, Laredo GJ, Vázquez NJR

Language: Spanish
References: 15
Page: 42-49
PDF size: 401.42 Kb.

ABSTRACT

Introduction: Brain metastases are the most common malignant lesions in the central nervous system. Brain metastases from pancreatic cancer are very rare, with poor prognosis. The present paper aims to describe a rare pathology and the work carried out for the patient's care.
Case report: 49-year-old man with personality changes, depression, and apathy. Five days before admission, he presented dysarthria, added left hemiparesis, and disorientation that progressed to sudden neurological deterioration that required advanced airway management. A computed tomography study was seen with cerebral cystic lesions. A decompressive craniectomy and drainage of the larger lesion was performed, with subsequent resection. The study protocol with immunohistochemistry reports CK 19, compatible with pancreatic adenocarcinoma.
Conclusions: A rare case of multiple brain metastases and suspected lung metastasis, both secondary to primary pancreatic adenocarcinoma was presented. The patient began with symptoms associated with brain lesions. The incidence of brain metastases with a primary pancreatic tumor is very low, and this is an exceptional case when presenting with neurological symptoms. Surgical resection of the brain lesion had a limited role in the clinical improvement of the patient since the progression of the disease was rapid. Still, it was useful to establish a diagnosis by immunohistochemistry. Since there are no screening tests for pancreatic tumors, it is difficult to identify them in early stages and without gastrointestinal symptoms.

REFERENCES

1. Kotecha R, Gondi V, Ahluwalia MS, Brastianos PK, MehtaMP. Recent advances in managing brain metastasis.F1000Research. 2018;7(Faculty Rev):1772. doi: 10.12688/f1000research.15903.1

2. Noh T, Walbert T. Brain metastasis: clinical manifestations,symptom management, and palliative care. HandbClin Neurol. 2018;149:75-88. doi: 10.1016/B978-0-12-811161-1.00006-2

3. Matsuo S, Amano T, Kawauchi S, Nakamizo A. Multiplebrain metastases from pancreatic adenocarcinomamanifesting with simultaneous intratumoral hemorrhages.World Neurosurg. 2019;123:221-5. doi: 10.1016/j.wneu.2018.12.036

4. Esmaeilzadeh M, Majlesara A, Faridar A, Hafezi M, HongB, Esmaeilnia-Shirvani H, et al. Brain metastasis fromgastrointestinal cancers: a systematic review. Int J ClinPract. 2014;68(7):890-9. doi: 10.1111/ijcp.12395

5. Sasaki T, Sato T, Nakai Y, Sasahira N, Isayama H, KoikeK. Brain metastasis in pancreatic cancer: Two case reports.Medicine (Baltimore). 2019;98(4):e14227. doi: 10.1097/MD.0000000000014227

6. Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma:Beyond first line, where are we? World J Gastroenterol.2021;27(17):1847-63. doi: 10.3748/wjg.v27.i17.1847

7. Vareedayah AA, Alkaade S, Taylor JR. Pancreatic adenocarcinoma.Mo Med. 2018;115(3):230-5.

8. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: A review.JAMA. 2021;326(9):851-62. doi: 10.1001/jama.2021.13027

9. He C, Huang X, Zhang Y, Lin X, Li S. The impact ofdifferent metastatic patterns on survival in patients withpancreatic cancer. Pancreatology. 2021;21(3):556-63. doi:

10. 10.1016/j.pan.2021.01.01410. Oka Y, Takano S, Kouchi Y, Furukawa K, Takayashiki T,Kuboki S, et al. Simultaneous brain and lung metastasesof pancreatic ductal adenocarcinoma after curative pancreatectomy:a case report and literature review. BMC Gastroenterol.2021;21(1):9. doi: 10.1186/s12876-020-01587-3

11. Papadimitriou K, Kiss-Bodolay D, Hedjoudje A, MillanDS, Simonin A, Fournier JY, et al. Late metachronouscerebral metastasis of pancreatic adenocarcinoma ofthe tail of the pancreas: a case report. J Med Case Rep.2022;16(1):144. doi: 10.1186/s13256-022-03314-w

12. Singhi AD, Koay EJ, Chari ST, Maitra A. Early detectionof pancreatic cancer: opportunities and challenges.Gastroenterology. 2019;156(7):2024-40. doi: 10.1053/j.gastro.2019.01.259

13. Mehrpouya M, Pourhashem Z, Yardehnavi N, OladnabiM. Evaluation of cytokeratin 19 as a prognostic tumoraland metastatic marker with focus on improved detectionmethods. J Cell Physiol. 2019;234(12):21425-35. doi:10.1002/jcp.28768

14. Menz A, Bauer R, Kluth M, von Bargen CM, GorbokonN, Viehweger F, et al. Diagnostic and prognostic impactof cytokeratin 19 expression analysis in human tumors: atissue microarray study of 13,172 tumors. Hum Pathol.2021;115:19-36. doi: 10.1016/j.humpath.2021.05.012

15. Jain R, Fischer S, Serra S, Chetty R. The use of Cytokeratin19 (CK19) immunohistochemistry in lesions of thepancreas, gastrointestinal tract, and liver. Appl ImmunohistochemMol Morphol. 2010;18(1):9-15. doi: 10.1097/PAI.0b013e3181ad36ea